## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.42 indicates fundamental undervaluation. Quality metrics strong (ROE 138%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-5.8% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($213.45)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73**
- Source: Simply Wall Street | 20251202T193951 | Neutral | Relevance: 99%
- AbbVie (NYSE:ABBV) announced an increase in its dividend to $1.73 per share, payable on February 17th, with a yield of 3.1%. While cash flow covers the dividend despite recent profit declines, the company's dividend growth potential is considered shaky due to a 22% annual EPS decline over the past five years, though earnings are predicted to rise in the next year. Investors should be aware of potential risks despite the consistent dividend policy.

**2. Willis Johnson & Associates Inc. Decreases Holdings in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251202T130831 | Bullish | Relevance: 99%
- Willis Johnson & Associates Inc. reduced its stake in AbbVie Inc. by 43.4% in Q2, selling 1,413 shares to hold 1,844 shares valued at $342,000. This comes as AbbVie surpassed Q3 earnings estimates with $1.86 EPS and $15.78 billion in revenue, and set strong Q4 guidance. The company also increased its quarterly dividend to $1.73, and analysts maintain a "Moderate Buy" rating with an average target price of $241.85.

**3. AbbVie (ABBV) Stock on December 2, 2025: Dividend Hike, Cancer Pipeline Momentum and 2026 Outlook**
- Source: ts2.tech | 20251202T211913 | Bullish | Relevance: 99%
- This article provides an in-depth analysis of AbbVie (ABBV) stock as of December 2, 2025, highlighting its recent dividend hike, momentum in its oncology and migraine pipelines, and positive outlook for 2026. It covers the stock's price, valuation, dividend profile, recent Q3 2025 earnings, strategic mergers and acquisitions, and Wall Street analyst ratings, while also addressing key risks for investors.

**4. AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73**
- Source: Simply Wall Street | 20251202T191409 | Somewhat-Bullish | Relevance: 99%
- AbbVie Inc. (NYSE:ABBV) has announced an increase in its dividend to $1.73, payable on February 17th, with the dividend yield approximately matching the industry average at 3.1%. While future dividend projections appear well-covered by cash flow despite past profit deficits, the company's EPS has declined by 22% per year over the last five years, raising concerns about long-term dividend sustainability even with predicted earnings growth in the next year. Investors should consider these factors alongside the company's solid track record of dividend growth.

**5. AbbVie Inc (ABBV) Stock on November 30, 2025: Analyst Downgrade, FDA Wins and Dividend Strength**
- Source: ts2.tech | 20251130T103626 | Somewhat-Bullish | Relevance: 98%
- AbbVie Inc. (ABBV) faces a mixed but generally constructive outlook as of November 30, 2025, with its stock up over 30% year-to-date despite a recent analyst downgrade from "Strong Buy" to "Buy" by Wall Street Zen. The company boasts significant FDA approvals for EPKINLY and progress with Skyrizi's reimbursement, along with a 5.5% dividend increase, highlighting strong fundamentals and pipeline momentum. While Medicare pricing pressures and accounting-driven earnings optics present caution flags, the overall sentiment remains bullish due to robust cash flow and strategic growth initiatives.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | HSBC | $265 | $225 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | HSBC | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.06M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.8% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.42 indicates undervaluation relative to growth. Forward P/E 15.7x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Analyst sentiment positive (1 raises, avg +18%). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $398.0B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.42 |
| Forward P/E | 15.7 |
| Current P/E | 21.1 |
| YoY Growth | 34.0% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from 2.7% to -3.0% (-5.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.0pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-0.72), momentum weakening. RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.02% (CS: 25) | Weak |
| RSI_14 | 45.5 | Neutral |
| MACD Histogram | -0.72 | Bearish |
| vs SMA20 | 0.987x | Below |
| vs SMA50 | 0.986x | Below |
| vs SMA200 | 1.099x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $224.37
- **Stop Loss:** $213.45 (4.9% risk)
- **Target:** $246.21 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 91
- **Position Value:** $20,417.67
- **Portfolio %:** 20.42%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*